Navigation Links
Pacira Pharmaceuticals, Inc. Announces Pricing of Follow-On Offering
Date:11/16/2011

PARSIPPANY, N.J., Nov. 16, 2011 /PRNewswire/ -- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced the pricing of its public offering of 7,000,000 shares of its common stock at a price of $6.50 per share. All of the 7,000,000 shares are newly issued and are being offered by Pacira, with expected net proceeds to Pacira of approximately $42.3 million after deducting underwriting discounts and commissions and estimated offering expenses. In addition, Pacira has granted the underwriters a 30-day option to purchase up to an additional 1,050,000 shares to cover over-allotments, if any.

Barclays Capital Inc. and Jefferies & Company, Inc. are acting as joint book-running managers for the offering. Piper Jaffray & Co., Wedbush PacGrow Life Sciences and Brean Murray, Carret & Co. are acting as co-managers for the offering.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. A registration statement relating to these securities has been filed with, and declared effective by, the Securities and Exchange Commission. A copy of the final prospectus for this offering may be obtained from Barclays Capital Inc., c/o Broadridge Financial Solutions, at 1155 Long Island Avenue, Edgewood, NY 11717, or by calling 1-888-603-5847 or by emailing Barclaysprospectus@broadridge.com. A copy of the final prospectus may also be obtained from Jefferies & Company, Inc., Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, telephone: (877) 547-6340, email
'/>"/>

SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress
2. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA)
3. Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment
4. Pacira Pharmaceuticals Announces FDA Acceptance of EXPAREL™ New Drug Application for Pain Management
5. Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Societys 57th Annual Meeting
6. Pacira Pharmaceuticals, Inc. Announces Pricing of Its Initial Public Offering
7. Pacira Pharmaceuticals Highlights Additional Safety Data on EXPAREL™ for Postsurgical Pain Relief at 2011 American Academy of Orthopaedic Surgeons Annual Meeting
8. Pacira Pharmaceuticals EXPAREL™ Data to be Featured at 2011 ASCPT 112th Annual Meeting
9. Pacira Pharmaceuticals to Present at the Barclays Capital 2011 Global Healthcare Conference
10. Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results
11. Pacira Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... SAN DIEGO , Dec. 17, 2014 /PRNewswire/ ... AEX: PHIA) and Volcano Corporation (NASDAQ: VOLC ), ... cardiovascular applications, today announced that they have entered into a ... a tender offer to acquire all of the issued and ... a total equity purchase price of USD 1 billion (approx. ...
(Date:12/17/2014)... With advancements in neurological and functional ... seeing new growth, according to Kalorama Information. Though ... the majority of market volume, newer 3T systems ... are creating opportunities for more sophisticated applications. The medical ... a rate of 4%, with world market revenues ...
(Date:12/17/2014)... 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... developing and commercializing innovative therapies addressing major unmet ... enrollment in its first Phase 2a study, RXI-109-1301.  ... the 1-month findings that were reported in September ... http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , , , ...
Breaking Medicine Technology:Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5
(Date:12/20/2014)... Parker & Sons, Inc. a focused and ... in contractor services announces reaching a milestone by providing ... of Arizona. Parker and Sons is comprised of a ... make customer service the number one priority. The company ... with one service vehicle and has since grown to ...
(Date:12/19/2014)... Today, Balfleet.com , a leading ... its formal dress promotion. All the old and new ... off. , Balfleet.com is well-known for its high quality ... dresses, cocktail dresses and more. Its formal dresses are ... and they can create an elegant look when paired ...
(Date:12/19/2014)... 20, 2014 Sweetdressy.com , a ... introduced its newest selection of cheap prom dresses for ... popular in the world and clients can buy these ... these prom dresses feature cool cuts and delicate craftsmanship, ... targeting the middle-end market. Discount shipping costs are available ...
(Date:12/19/2014)... FL (PRWEB) December 19, 2014 ... Revitalizing Bedsheets are now available. Celliant, the world’s ... both sheets and pillowcases. , There are a ... proven additional circulation, increased oxygenation and balanced body ... faster healing and pain relief; enhanced athletic performance; ...
(Date:12/19/2014)... Branson, Missouri (PRWEB) December 19, 2014 ... a new official world record -- for the first time ... most prestigious record book, Guinness World Records 2015, listing the ... Steepest Wooden Roller Coaster. In additional awards announced this week, ... to See Christmas Lights in the US,” USA Today’s 10Best ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Reaching A Milestone By Providing 40 Years Of Dedicated Contractor Services For Homeowners Of Arizona 2Health News:Parker & Sons Announces Reaching A Milestone By Providing 40 Years Of Dedicated Contractor Services For Homeowners Of Arizona 3Health News:Balfleet.com Announces Its Formal Dress Promotion For 2015 2Health News:Cheap Prom Dresses Online Now at Sweetdressy.com 2Health News:Energy Textiles Launches Celliant Revitalizing Bedsheets 2Health News:Silver Dollar City Nets New Titles: Guinness Book of World Records, Plus CNN Travel, USA Today & Fodor’s Top Places for Christmas Lights 2
... , WEDNESDAY, Aug. 18 (HealthDay News) -- Although it,s long ... produce any insulin after they,ve had the disease for a ... by type 1 diabetes may actually be in a constant ... decades. , This new research stems from a study ...
... for more than 1,800 years reduced the gastrointestinal side ... effects of the cancer treatment, Yale University researchers report. ... four herbs, called PHY906, and is based on a ... treat nausea, vomiting and diarrhea. The study, published August ...
... Goodwin HealthDay Reporter , WEDNESDAY, Aug. 18 (HealthDay ... cigarettes have emerged as one of the most controversial products ... to them, with nearly 45 percent of smokers aged 12 ... Survey on Drug Use and Health. Most black teenaged smokers ...
... (CHICAGO) Neurological and infectious disease experts at Rush University ... treatment of individuals with West Nile fever or suspected central ... Rush is the only site in the Midwest enrolling patients ... called PARADIGM. The new drug treatment for West ...
... health and science communications firm, announced the results of ... children identified with a rare, fatal, and rapid aging ... a Centers for Disease Control national conference on health ... living in 30 countries had been identified with Progeria, ...
... Middle-aged and elderly Swedish women who regularly ate a small ... in a study reported in Circulation: Heart Failure , ... conducted among 31,823 middle-aged and elderly Swedish women, looked at ... ate, compared to their risk for heart failure. The quality ...
Cached Medicine News:Health News:Long-Term Type 1 Diabetes 'Survivors' Give Clues to the Disease 2Health News:Long-Term Type 1 Diabetes 'Survivors' Give Clues to the Disease 3Health News:FDA Mulling Ban on Menthol Cigarettes 2Health News:FDA Mulling Ban on Menthol Cigarettes 3Health News:FDA Mulling Ban on Menthol Cigarettes 4Health News:Study to examine new treatment for West Nile virus 2Health News:Global media campaign finds 'hidden' children with rare, fatal aging disorder 2Health News:Moderate chocolate consumption linked to lower risks of heart failure 2Health News:Moderate chocolate consumption linked to lower risks of heart failure 3
... a cast from an arm or leg can ... cut or burned by the cast saw blade. ... remove any cast with confidence. This innovative, cut-resistant ... burns from the cast saw and can be ...
... bypass grafting or creation of a vascular ... tunnel is of the utmost importance in ... answer for those seeking a high-precision tunneling ... the risk of twisting or kinking for ...
... In pediatric cardiac surgery, modified Blalock-Taussig ... prior to total correction. GORE-TEX Vascular Grafts ... of surgeons worldwide for use as shunts ... offer such benefits as ease of implantation ...
... have met the challenges of the most ... Recognized for exceptional performance and quality, they ... worldwide. These grafts require no preclotting, resist ... assure utmost thrombectomy safety. The Gore vascular ...
Medicine Products: